Oh S, Mao X, Manfredo Vieira S, Lee J, Patel D, Choi E, et al. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat Biotechnol. 2023;41:1229-1238 pubmed publisher

Chakrabarti L, Chaerkady R, Wang J, Weng S, Wang C, Qian C, et al. Mitochondrial membrane potential-enriched CHO host: a novel and powerful tool for improving biomanufacturing capability. MAbs. 2022;14:2020081 pubmed publisher

Roerden M, Wirths S, Sökler M, Bethge W, Vogel W, Walz J. Impact of Mantle Cell Lymphoma Contamination of Autologous Stem Cell Grafts on Outcome after High-Dose Chemotherapy. Cancers (Basel). 2021;13: pubmed publisher

Xu Y, Fulciniti M, Samur M, Ho M, Deng S, Liu L, et al. YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma. Blood. 2020;136:468-479 pubmed publisher

Garfall A, Stadtmauer E, Hwang W, Lacey S, Melenhorst J, Krevvata M, et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight. 2018;3: pubmed publisher

Faitschuk E, Nagy V, Hombach A, Abken H. A dual chain chimeric antigen receptor (CAR) in the native antibody format for targeting immune cells towards cancer cells without the need of an scFv. Gene Ther. 2016;23:718-726 pubmed publisher

Bhoj V, Arhontoulis D, Wertheim G, Capobianchi J, Callahan C, Ellebrecht C, et al. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood. 2016;128:360-70 pubmed publisher